Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Pharmaceutical K.K.
Memorial Sloan Kettering Cancer Center
Northwestern University
Hoffmann-La Roche
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Mayo Clinic
University of Washington
Medical University of South Carolina
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center